March 01, 2012

Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant

 

Genzyme Begins Shipping Fabrazyme from Newly Approved Framingham Manufacturing Plant

Paris, France – March 1, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme today announced that Genzyme has begun shipping Fabrazyme® (agalsidase beta) produced at its newly approved plant in Framingham, Massachusetts. As previously communicated, patients in the U.S. are now able to return to full dosing in March. In addition, all new patients in the U.S. are eligible to begin Fabrazyme treatment, at full dosing levels.